Fed. Circ. Won't Rehear Prandin Use Code Patent Case

Law360, New York (July 30, 2010, 4:59 PM EDT) -- Unmoved by calls from the generic-drug industry to revisit the decision, a federal appeals court has refused to reconsider en banc an April ruling for Novo Nordisk A/S in its patent fight with Caraco Pharmaceutical Laboratories Ltd. over the diabetes drug Prandin.

The U.S. Court of Appeals for the Federal Circuit said Thursday that it would not reconsider its April 14 split ruling for Novo Nordisk, a finding the generics industry says will hamper the U.S. Food and Drug Administration's ability to process generic drug applications....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.